Litigation Summary and Patent Infringement Analysis: Allergan Inc. v. Wilshire Pharmaceuticals Inc. (1:14-cv-01461)
Last updated: July 24, 2026
Executive summary
Case: Allergan Inc. v. Wilshire Pharmaceuticals Inc., 1:14-cv-01461 (D. Del.).
Core dispute: Allergan’s patent estate asserted against Wilshire in connection with a Paragraph IV-type generic entry challenge tied to an Allergan branded pharmaceutical product (drug identity not provided in the prompt).
Business impact: Outcome and claim construction determine whether Wilshire could launch on a competitive clock tied to Orange Book exclusivities and patent expirations, and whether Allergan’s asserted claims block or narrow generic commercialization.
What patents were at issue in Allergan v. Wilshire Pharmaceuticals (1:14-cv-01461)?
The prompt does not provide the drug name, asserted patent numbers, claim chart themes, or the court’s Markman/claim construction orders.
Without the asserted patent list and underlying Orange Book reference for the Abbreviated New Drug Application (ANDA), a complete infringement and validity analysis cannot be produced.
What typically gets litigated in an Allergan v. Wilshire generic case?
Infringement: Whether the Wilshire product, as described in the ANDA and/or proposed label, falls within each asserted claim (composition, formulation, method-of-use, or manufacturing method).
Invalidity: Anticipation/obviousness (35 USC §§102/103), indefiniteness (35 USC §112(b)), written description/enablement (35 USC §112(a)), and sometimes lack of utility.
Non-infringement defenses: Design-around of claim elements, differences in formulation parameters, dosing steps, or controlled-release/microstructure features depending on drug class.
ANDA procedure: Timing and jurisdictional requirements for Paragraph IV notice and suit filing under 35 USC §271(e)(2).
Why did Allergan sue Wilshire in 1:14-cv-01461, and what was the Paragraph IV trigger?
The prompt does not identify the ANDA number, the listed Orange Book patents, the Paragraph IV certification(s), or the district court’s docket filings that specify the triggering event.
A proper litigation narrative requires the factual predicate: which patents Wilshire challenged, when notice was sent, and which exclusivities were in force.
Litigation timeline components that drive entry risk
ANDA filing date and Paragraph IV certification date
Orange Book patent expiration dates
Eighteen-month stay status (if triggered) and any lifting events
Scheduling order for claim construction and infringement/validity phases
Settlement vs adjudication (if the record shows an agreement)
What did the court decide: infringement, invalidity, or both?
The prompt does not provide final judgment, summary judgment outcomes, Markman findings, or dismissal/voluntary termination orders.
A defensible analysis must map court outcomes to each asserted claim set and explain whether Wilshire prevailed on any of:
claim construction that narrows infringement,
obviousness/anticipation invalidation,
or non-infringement for the accused product.
Claim construction is usually decisive in ANDA patent suits
If the case included method-of-use claims, the court often construes “use” elements tightly to avoid broad label capture.
If composition/formulation claims were asserted, construction often turns on:
and manufacturing process parameters when tied to structural outcomes.
How strong is Allergan’s patent estate in this dispute?
Strength assessment requires:
the asserted patent numbers and assignees,
prosecution history indicators (e.g., narrowed claims),
and judicial outcomes (validity and infringement rulings).
None of those inputs are present in the prompt, so a complete strength rating cannot be produced.
Did Wilshire challenge the patents under specific invalidity theories (obviousness, anticipation, §112)?
No invalidity grounds are provided.
An infringement/validity “case theory” summary must cite:
prior art patents/publications,
claim limitations alleged to be disclosed,
and the court’s findings on each element.
What is the settlement and commercial entry impact for Allergan vs Wilshire?
Settlement terms, launch date commitments, design-around obligations, and payment/licensing terms are not included in the prompt.
Without docket outcomes and/or settlement documents, it is not possible to quantify:
whether Wilshire launched,
whether Allergan obtained dismissal or injunctions,
and whether the dispute resulted in a license.
What is the Orange Book status for the drug(s) implicated in 1:14-cv-01461?
The Orange Book listing (patent numbers, expiration dates, exclusivity types, and listed dosage forms) depends on the drug name and ANDA reference drug.
The prompt does not specify the implicated product, so Orange Book status cannot be enumerated.
What generic entry risks existed for Wilshire if Allergan won (or lost)?
Generic launch risk depends on the exact:
patent claims and their remaining life,
exclusivity stack,
and injunction scope.
The required inputs (asserted patents, remaining expiration windows, and claims scope) are not provided.
How do other Allergan generic challenges compare with 1:14-cv-01461?
Comparative analysis requires at least:
which Allergan product class is involved (e.g., ophthalmic, CNS, GI, aesthetics),
whether asserted patents are formulation vs method-of-use vs manufacturing,
and whether courts in related cases reached similar constructions.
The prompt does not identify the drug or asserted patent patterns.
Key Takeaways
This prompt does not contain the drug identity, asserted patent numbers, or court rulings necessary for a complete litigation summary and technical patent analysis.
A business-grade infringement/invalidity assessment and an Orange Book exclusivity and entry-risk mapping cannot be completed from the docket number alone without the missing case record details.
FAQs
What is a Paragraph IV certification and how does it relate to Allergan v. Wilshire-type ANDA litigation?
How do Markman claim construction outcomes typically affect generic infringement in ANDA cases?
What does an Orange Book listing determine in terms of stay, injunctions, and launch timing?
When do settlements in generic patent suits convert into licensing deals with design-around requirements?
What is the usual evidence basis for infringement and non-infringement in formulation and method-of-use claims?
References
(No sources can be cited from the provided prompt.)
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models.
By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
